

## Supplementary data file. Secondary outcome measures

	Study Population n=46						
	Baseline	End of open label phase	Long-term follow-up	Change score (Long-term follow-up vs end of open label phase)	p value	Change Score (Long-term follow-up vs baseline)	p value
<b>CGI-S</b>	5 (4;6)	4 (2;5)	4 (2;5)	0 (-1;1)	0.69	-1 (-2;0)	<b>0.00</b>
<b>VAS</b>	56 (36;77)	25 (2;62)	55 (30;76) *	15 (-13;53)*	<b>0.02</b>	1 (-23;24)*	0.97
<b>Physical Functioning</b>	56 (40;95)	65 (36;100)	65 (40;90)*	-5 (-15;9)*	0.46	0 (-10;8)*	0.57
<b>BDI</b>	8 (5;14)	6 (3;13)	8 (2;11) *	0 (-5;3)*	0.83	-2 (-6;0)*	<b>0.02</b>
<b>BAI</b>	12 (7;16)	7 (4;15)	9 (3;14)*	2 (-3;5)*	0.33	0 (-6;3)*	0.33

**Table 1.** Summary of the outcome measures all expressed as median and Inter Quartile ranges (IQR). CGI-S = Clinical Global Impression - Severity; VAS= Visual analogue scale; BDI=Beck depression inventory; BAI=Beck Anxiety Inventory. Physical Functioning scale of the 36-Item Short Form Health Survey. \*Data of N=31 patients.